This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 14.29% and 2.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 32.35% and 5.89%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
Zacks.com featured highlights include ICU Medical and Ardmore Shipping
by Zacks Equity Research
ICU Medical and Ardmore Shipping are part of the Zacks Screen of the Week article.
ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 33.05% and 4.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
2 Stocks in Focus as New Analysts Initiate Coverage
by Shrabana Mukherjee
The recent surge in analyst coverage for stocks such as ICU Medical (ICUI) and Ardmore Shipping (ASC) indicates the potential for significant price appreciation in the near term.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BellRing Brands (BRBR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 10.26% and 5.51%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor (OMI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Owens & Minor (OMI) delivered earnings and revenue surprises of 22.22% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About ICU Medical (ICUI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ICU Medical (ICUI) stock based on the movements in the options market lately.
ICU Medical's (ICUI) Plum Duo With Safety Shield Gets 510(k) Nod
by Zacks Equity Research
The Plum Duo infusion pump represents the latest addition to ICU Medical's (ICUI) advanced lineup of infusion devices.
ICU Medical (ICUI) Beats Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 21.29% and 2.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.85% and 2.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) Up 26% in a Year: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.
UnitedHealth's (UNH) Program to Aid Georgia's Diabetic Patients
by Zacks Equity Research
UnitedHealth's (UNH) unit, UnitedHealthcare, extends its community-based program to improve the health conditions of Southwest Georgia's diabetic patients.
Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?
by Zacks Equity Research
Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to a growing customer base, numerous contract wins and solid cash-generating abilities.
ICU Medical (ICUI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 26.09% and 2.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Beats Q4 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?